Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag Olamine in Chronic ITP
NCT02403440Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hetrombopag in immune thrombocytopenia (ITP), sponsored by Hengrui. Primary endpoint: Number of volunteers with adverse events at Day 28. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02403440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403440.